High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection
Launched by SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Aug 16, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different treatment plans for a common stomach infection called Helicobacter pylori (H. pylori). This bacteria can cause problems like ulcers and is often treated with antibiotics. The study wants to compare a high-dose dual therapy to a quadruple therapy that includes a medication called minocycline. They will enroll 200 adults who have tested positive for H. pylori to see how effective these treatments are, how well patients tolerate them, and whether the bacteria show any resistance to the antibiotics used.
To participate in this study, patients need to be between 18 and 80 years old and must have a confirmed H. pylori infection. However, individuals who are pregnant, have certain serious health conditions, or have had major stomach surgery in the past cannot join. Participants will undergo some tests to check the bacteria and its sensitivity to different antibiotics. They will receive treatment and then be monitored for any side effects or complications. This trial is currently recruiting participants, and it aims to help improve treatment options for H. pylori infections in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ability and willingness to participate in the study and to sign and give informed consent
- • Confirmed H. pylori infection
- Exclusion Criteria:
- • Pregnant and lactating women;
- • History of gastrointestinal malignancies;
- • History of previous subtotal gastrectomy;
- • Serious dysfunction of heart, liver, kidney, lung and other important organs and congenital diseases; Such as grade IV cardiac insufficiency, liver failure, uremia, respiratory failure, hemophilia, Wilson disease, etc;
- • History of hematological diseases
- • People who are allergic to drugs;
- • The guardian or patient refused to join the group;
- • Alcohol and / or drug abuse (addiction or dependence) or poor compliance judged by doctors;
- • No legal capacity or poor self-knowledge
- • administration of antibiotics, bismuth, antisecretory drugs, or Chinese herb medicine in the preceding 8 weeks
About Shanghai Jiao Tong University School Of Medicine
Shanghai Jiao Tong University School of Medicine is a leading academic institution in China, renowned for its commitment to advancing medical research and education. As a prominent clinical trial sponsor, the school leverages its extensive expertise in biomedical sciences and innovative healthcare solutions to conduct rigorous clinical studies aimed at improving patient outcomes. With a focus on collaboration and translational research, the institution fosters partnerships with healthcare providers, industry leaders, and regulatory bodies to ensure the highest standards of scientific integrity and ethical conduct in clinical trials. Through its research initiatives, Shanghai Jiao Tong University School of Medicine strives to contribute significantly to the global medical community and enhance the quality of healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xuchang, Henan, China
Shanghai, Shanghai, China
Luoyang, Henan, China
Jiaozuo, Henan, China
Zhengzhou, Henan, China
Zhengzhou, Henan, China
Zhoukou, Henan, China
Hebi, Henan, China
Pingdingshan, Henan, China
Zhengzhou, Henan, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported